Sermorelin GHRH-R Research: GH Axis Signalling in Male Cell Model Studies
Receptor Pharmacology and Mechanism of Action
Sermorelin acts via GHRH-R (class B GPCR) Gs/cAMP/PKA signalling pathways in cellular research models. Competitive radioligand binding assays and functional receptor activation studies demonstrate its selective engagement with growth hormone-releasing hormone receptors expressed in pituitary somatotroph cell lines. The compound exhibits nanomolar binding affinity (Kd ~0.5-2.0 nM) in saturation binding experiments using [125I]-GHRH as the radioligand tracer in CHO-K1 cells transfected with human GHRH-R constructs.
Sermorelin's pharmacological profile shows competitive antagonism with native GHRH(1-44) in displacement binding assays, with IC50 values ranging from 1-5 nM across different cell expression systems. The peptide demonstrates full agonist activity at GHRH receptors, producing dose-dependent activation of adenylyl cyclase and subsequent cAMP accumulation with EC50 values typically between 0.1-1.0 nM in functional assays.
GHRH Receptor Structure-Activity Relationships
The 29-amino acid sequence of sermorelin represents the biologically active N-terminal fragment of native GHRH(1-44). Structure-activity relationship studies in transfected cell models reveal that the first 29 residues contain the complete receptor binding domain and signalling activation sequences. Alanine-scanning mutagenesis experiments demonstrate critical importance of residues 1-4 for receptor binding affinity, while the C-terminal region (residues 15-29) contributes to receptor selectivity and signalling efficacy.
Molecular modelling studies combined with photoaffinity labelling experiments map the sermorelin binding site to the extracellular N-terminal domain and extracellular loops of GHRH-R. The peptide's α-helical conformation, particularly within residues 6-27, facilitates optimal receptor engagement and G-protein coupling efficiency in cell-based assay systems.
Intracellular Signalling Pathways
cAMP-PKA Cascade Activation
Upon receptor binding, sermorelin triggers Gs protein coupling and adenylyl cyclase activation in somatotroph cell models. Time-course experiments demonstrate rapid cAMP elevation within 30 seconds of peptide application, reaching peak levels at 2-5 minutes with sustained elevation for 15-30 minutes. This cAMP response shows concentration-dependent characteristics with Hill coefficients near unity, indicating simple 1:1 receptor-ligand interactions.
Protein kinase A activation downstream of cAMP accumulation occurs within 1-2 minutes of sermorelin treatment in HEK293 cells expressing GHRH-R. PKA substrate phosphorylation assays reveal robust activation of the catalytic subunit, leading to phosphorylation of downstream targets including CREB at serine-133 residues.
Transcription Factor Modulation
CREB phosphorylation initiates transcription factor activation cascades in pituitary cell culture models. Electrophoretic mobility shift assays demonstrate enhanced CREB-DNA binding activity within 10-15 minutes of sermorelin treatment. ChIP-seq analysis in GH3 pituitary cells reveals sermorelin-induced CREB recruitment to growth hormone gene promoter regions and other cAMP-responsive genetic loci.
Additional transcription factors activated include STAT5b through JAK2-mediated phosphorylation cascades, creating complex gene expression networks in responding cell populations. Real-time PCR analysis shows peak mRNA elevation occurring 2-4 hours post-treatment across multiple growth-related transcripts.
Cell Model Applications
Pituitary Somatotroph Systems
Primary rat pituitary cell cultures provide physiologically relevant model systems for sermorelin pharmacology research. These preparations maintain native receptor expression patterns and signalling pathway integrity for 7-14 days in defined media conditions. Flow cytometry analysis demonstrates sermorelin responsiveness in 60-80% of dissociated pituitary cells, correlating with immunofluorescent identification of somatotroph populations.
Immortalised cell lines including GH3, GH4C1, and RC-4B/C provide reproducible experimental platforms for mechanistic studies. These models express endogenous GHRH receptors and maintain cAMP-responsive gene expression programs characteristic of primary somatotrophs.
Transfected Expression Systems
HEK293 and CHO-K1 cells transfected with human GHRH-R constructs enable detailed pharmacological characterisation studies. These systems permit manipulation of receptor expression levels, investigation of receptor mutants, and analysis of selective signalling pathway components through targeted gene knockout or overexpression approaches.
Research Summary
Sermorelin demonstrates potent and selective GHRH receptor agonist activity in diverse cell model systems, activating Gs-coupled signalling cascades with nanomolar potency. The compound's well-characterised pharmacological profile, combined with its stability in cell culture conditions, makes it a valuable research tool for investigating growth hormone axis signalling pathways. Current in vitro applications span receptor pharmacology, signal transduction analysis, and transcriptional regulation studies in both primary and immortalised cell culture models.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Hexarelin
TB-500
Epithalon
Ipamorelin
Tirzepatide
CJC-1295 DAC
PT-141
Semaglutide
Selank
BPC-157
Sermorelin
Melanotan 2
IGF LR3
Tesamorelin
AICAR
IGF-DES
GHRP 2
Albuterol
Tamoxifen
Letrozole
Clomiphene
Tadalafil
Clenbuterol
Anastrozole
Finasteride
Exemestane
Sildenafil
Yohimbine
Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows
Already a customer? Sign In
Create Account
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
Sarms
Stacks
Research Liquids
Albuterol 5MG/ML | 30ML with dropper
Anastrozole 1.5MG/ML | 30ML with dropper
Clomiphene 50MG/ML | 30ML with dropper
Finasteride 5MG/ML | 30ML with dropper
Letrozole 3.5 MG/ML | 30ML with dropper
LiquiCia 30MG/ML | 30ML with dropper
LiquiCia T50 50MG/ML | 30ML with dropper
LiquiClen 200MCG/ML | 30ML with dropper
Liquistane / Exemestane 25MG/ML | 30ML with dropper
LiquiTamo 20MG/ML | 30ML with dropper
LiquiVia 25MG/ML | 30 ML with dropper
T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper
Toremifene Citrate 60MG/ML | 30ML with dropper
Yohimbine HCL 10MG/ML | 30ML with dropper
Research Peptides
Aicar 50MG
BPC-157 + TB-500 Blend 2mg ea/ 4MG
BPC-157 5MG
CJC-1295 + DAC 2MG
CJC-1295 | No DAC 2MG
Epithalon 10MG
Frag Premium 176-191 5MG
GHK-CU Copper Peptide 50MG
GHRP-2 5MG
GHRP-6 5MG
Hexarelin 5MG
IGF-1 DES 1MG
IGF-1 LR3 1MG
Ipamorelin 5MG
Melanotan 2 10MG
NAD+ 500MG
PT-141 / Bremelanotide 10MG
GLP-1/GIP/GCG (RT)
Selank 5MG
GLP1 (SM)
Sermorelin 5MG
TB-500 5MG
GIP/GLP-1 (TZ)
PDE5 Inhibitors
GLP-1
Diluents
Bacteriostatic Water 10ML